FORT WORTH, Texas, June 2, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that it has acquired Regranex® Gel, along with the corresponding intellectual property (including patents), from Systagenix.

BETHESDA, Md., March 16, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO).

FORT WORTH, Texas, Feb. 23, 2011 /PRNewswire/ -- Healthpoint today announced the launch of a new corporate identity featuring a new company name, Healthpoint Biotherapeutics, along with an updated brandmark and corporate tagline, "The Science of Healing(TM)".

LAS VEGAS, Jan. 4, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds, CVBT-141B.

DURHAM, N.C., Dec. 3, 2010 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (Nasdaq: OXBT) (SIX Swiss Exchange: OXBT) today announced that the Company plans to report second quarter fiscal year 2011 financial results on Thursday, December 9, 2010.